Compare DRUG & NAVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DRUG | NAVI |
|---|---|---|
| Founded | 2019 | 1973 |
| Country | United States | United States |
| Employees | N/A | 670 |
| Industry | Pharmaceuticals and Biotechnology | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.1M | 802.7M |
| IPO Year | 2020 | N/A |
| Metric | DRUG | NAVI |
|---|---|---|
| Price | $83.37 | $8.46 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 6 | 6 |
| Target Price | ★ $129.25 | $10.00 |
| AVG Volume (30 Days) | 195.9K | ★ 857.1K |
| Earning Date | 05-15-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 6.73% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $76.23 |
| Revenue Next Year | N/A | $15.73 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.18 | $7.80 |
| 52 Week High | $123.75 | $16.07 |
| Indicator | DRUG | NAVI |
|---|---|---|
| Relative Strength Index (RSI) | 50.80 | 48.48 |
| Support Level | $79.55 | $7.83 |
| Resistance Level | $84.29 | $8.79 |
| Average True Range (ATR) | 4.91 | 0.28 |
| MACD | -0.47 | -0.02 |
| Stochastic Oscillator | 61.99 | 51.26 |
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Navient Corp provides technology-enabled education finance solutions that simplify complex programs and help millions of people achieve success. The company operates its business in two segments: Federal Education Loans, and Consumer Lending. A majority of its revenue is generated from the Federal Education Loans segment, in which the company owns and manages the Federal Family Education Loan Program (FFELP) loans, generating revenue mainly in the form of net interest income. The Consumer Lending segment owns and manages private education loans and is the master servicer for these portfolios. Through its Earnest brand, the company also refinances and originates in-school private educational loans.